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Introduction
Sarcomas are an extremely uncommon group of malignancies 
arising from mesenchymal (non-epithelial or connective) 
tissues. Overall, they constitute 1% of human malignancies 
with an annual incidence rate of fewer than 5 patients per 
million (1,2). Sarcoma may arise from any mesenchymal cell 
lineages including fat, muscle, or connective tissue. Overall, 
over 50 different individual histological sarcoma subtypes 
have been described. Due to the rarity of these groups of 
malignancies, many subtypes were, and still today to a large 
extent, are managed as a single entity. 
Overall patients with soft tissue sarcoma (STS) will 
present with either localized or metastatic disease. 
Approaches for localized disease generally primarily focus on 
the use of surgical extirpation to remove the tumor; ideally 
with a margin-negative resection, usually without lymph 
node resection. Such surgeries can result in significant overall 
cure rates. In the setting of localized STS, radiation therapy 
may serve as an adjunct for local control in the setting of 
close margins with high-grade disease (3). Based upon tumor 
type and grade, chemotherapy is an additional adjunct 
that remains somewhat controversial for resectable disease 
depending upon the specific tumor type. Chemotherapy, 
however, is certainly beneficial for some subtypes and, like 
radiation therapy, most likely beneficial for higher-grade 
tumors. The role of chemotherapy, nonetheless, although 
clearly beneficial for some high-grade STS subtypes, remains 
somewhat controversial as both phase II and population-
based studies demonstrate minimal to no benefit in overall 
survival on top of surgery and no improvement in survival for 
many subtypes with metastatic disease (4).
Although the role of adjuvant therapies is modest in 
the management of STS, over half of all STS patients 
will survive beyond 5-years following presentation. As 
targeted therapies have been introduced, survival rates 
have dramatically improved for certain subtypes, such as 
GIST. For other STS types outcomes have not changed 
(5-7). This review focuses on integrating therapies around 
the treatment of the STS patient with a focus on overall 
management and surgical considerations.
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Presentation
STS generally present as a painless mass that may be slow 
growing or rapidly expanding. The differential diagnosis 
for masses noted by exam or cross-sectional imaging is 
broad and can include benign tumors, adenocarcinomas, 
and lymphomas. STS arising in the head and neck or 
extremity usually present with tumors under 5 cm in size 
as the patients’ frequently notice and seek attention for 
new painless masses (8). However, diagnosis can be initially 
delayed due to the concealed anatomic location of the mass, 
such as within the abdomen, thorax or retroperitoneum. 
Tumors in these areas can develop extremely large in size 
and may be diagnosed following cross-sectional imaging 
frequently for vague symptoms, such as pain, impaired 
function of the invaded organs or incidentally discovered for 
other reasons. As a general rule, STS arising in the trunk 
with greater invasive or desmoplastic biology will present 
earlier and with smaller size as adjacent organ invasion may 
cause obstruction of bowel, ureter or other hollow viscus 
structures (9,10). Of truncal sarcomas, thoracic STS tend to 
present at the smallest size, as these masses frequently will 
cause organ compression resulting in dyspnea or cardiac 
function problems. For both abdominal and retroperitoneal 
tumors, larger sizes are more common, as these locations 
can be associated with minimal symptoms even at very 
large sizes. Tumors arising in the retroperitoneum 
frequently are the least symptomatic and present on average 
with the largest tumor sizes. In fact, over two-thirds of 
retroperitoneal tumors present over 10 cm in diameter with 
20–30 cm masses not being infrequent (11,12). 
STS types by location
Regarding distribution, STS in adults arise most commonly 
in the trunk or retroperitoneum (62%), extremity (30%) or 
head and neck area (7%). Among STS, the most common 
types are leiomyosarcoma (LMS) and gastrointestinal 
stromal tumors (GIST) (together accounting for 40% of 
STS), followed by undifferentiated pleomorphic sarcoma/
malignant fibrohistiosarcoma (MFH; 30%), liposarcoma 
(20%), fibrosarcoma (6%) and other tumor types (4%) 
(1,2,11,13). In head and neck tumors, MFH is most 
common sarcoma (8,14). In the trunk, LMS/GIST are the 
most common while in the retroperitoneum, liposarcoma is 
the most common (13). 
In adults,  sarcoma incidence has been noted to 
be increasing in the population with an incidence of 
30–35 cases per 1,000,000 population. This increase is likely, 
in part, related to the increasing utilization of cross-sectional 
imaging revealing incidental slow-growing masses. Risk of 
developing sarcoma is more common after age 50 years with 
a stable incidence being observed after that age (2,10,13).
Is there a need for tissue diagnosis? 
The great variety of tumor types and the potential for 
different optimal therapeutic approaches support the 
routine biopsy to obtain a clear histologic diagnosis 
prior to initiating treatment. Differential diagnosis 
may, based upon cross-sectional imaging information, 
include inflammatory, benign, locally aggressive tumors, 
STS and other malignancies. Biopsy, either obtained by 
core-needle or open techniques may prevent surgery in 
instances where a mass may not represent sarcoma or may 
allow initiation of alternative therapies such as a targeted 
neoadjuvant approach potentially as part of a clinical trial. 
That being said, in instances where the diagnosis can be 
accurately ascertained by cross-sectional imaging, where 
severe symptoms exist or if the differential includes tumors 
that would all benefit from resection, then a preoperative 
tissue diagnosis may not be necessary prior to resection. 
Examples of this would include large retroperitoneal 
masses, particularly those with a density consistent with 
fat, hypervascular gastric masses consistent with GIST, or 
instances of a likely sarcoma with intestinal obstruction. 
Care should be exercised if resection is planned without a 
prior tissue diagnosis, as conditions such as lymphoma may 
mimic those of sarcoma in many locations including the 
pelvis, groin and retroperitoneum (15-18).
Biopsy approach
For patients where a core or open biopsy is planned, 
consideration as to how to approach the tumor biopsy is 
important. Generally, regardless if an open or core biopsy is 
planned, the tract should be placed in such a way as it might 
be excised during the definitive resection to both hopefully 
optimize local control and prevent tumor seeding (19).  
Some authors prefer a core biopsy to make a diagnosis of 
STS. This certainly is useful for cases of intestinal sarcoma 
where a diagnosis may be unclear or targeted neoadjuvant 
chemotherapy for GIST planned. Core biopsy is also an 
excellent first approach in settings where a local recurrence 
of disease or metastases is suspected. Furthermore, if 
preoperative concerns regarding subjecting a patient to 
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open biopsy due to their overall health, comorbidities, or 
tumor location may also justify a core biopsy. In such cases 
a core biopsy may allow a rapid diagnosis of recurrence and 
allow implementation of a variety of non-surgical therapies 
if warranted (16,20-22). Many clinicians prefer an open 
biopsy to a core biopsy especially in locations where an 
open biopsy can be easily and safely obtained. This is mainly 
because it can be hard to make the diagnosis on core biopsy 
due to large amount of necrotic tissue. Furthermore, the 
limited tissue provided by a core biopsy may miss higher-
grade components of the tumor. Nonetheless, a core biopsy 
may be used as a first attempt to obtaining a diagnosis if 
it may be obtained expediently. The reader is cautioned, 
however, to recognize that if obtaining a core biopsy might 
ultimately delay diagnosis and implementation of care, 
consideration to immediately proceeding to a definitive 
open biopsy may be optimal (23-25). 
In the extremity and more superficial areas of the 
trunk, biopsy for patients with a new soft tissue mass is 
generally best accomplished by open biopsy. Considerations 
regarding the incision would be to place it in such a way 
as to allow easy re-excision of the mass during definitive 
care. Generally this is done by making the incision along 
the long axis of an extremity, overlying the mass of 
interest. Transverse incisions over the extremity may be 
suboptimal as they may be difficult to fully re-excise and 
may complicate subsequent incisional closure and healing 
due to blood-flow disruption. Usually biopsies are planned 
as incisional rather than excisional, as total removal of a 
mass at initial biopsy may make subsequent margin-negative 
surgery difficult to achieve. Nonetheless, excisional biopsy 
is reasonable and may be a better option for smaller tumors 
such as those under 5 cm. These smaller masses frequently 
will prove not to be malignant and may allow a patient to 
not undergo a second procedure (25,26).
Localized disease: the principles of surgical resection
For STS, surgery has been recognized as the main therapy 
for patients, and one that can provide the most significant 
chance for palliation, long-term survival and the only therapy 
associated with cure. Although a multidisciplinary approach 
is necessary in most cases, the management of resectable STS 
should have key input from the surgeon due to the critical 
role for surgery in optimizing the pre-operative planning and 
approach to resection (3,12,14,25,27).
Theoretical operative objectives for all STS are similar 
and focus on obtaining a margin-negative resection 
generally without need for lymphadenectomy. Many experts 
suggest that 1–2 cm negative margins or inclusion of an 
additional plane of uninvolved tissue should be the goal of 
surgery (3,28-30). However, some studies suggest that a 
margin-negative resection, regardless of margin distance, 
provides similar local control rates (31). Close margins may 
be encountered particularly in large truncal tumors as the 
ability to provide a margin-negative resection is complicated 
by the presence of adjacent critical anatomical structures 
necessitating a microscopic (R1) or macroscopic (R2) 
positive resection. Furthermore, R1 resections may still be 
curative as the patients undergoing R1 resection frequently 
do not demonstrate recurrent disease except when tumor 
characteristics are unfavorable (such as, high grade tumors) 
(3,8,14,27,29). In such cases, local recurrence rate can be 
high, ranging from 30% in R1 resection vs. 10% in R0 
resections. Consideration should be given for adjuvant 
radiotherapy in cases of R1 resection, particularly with high 
grade malignancies (3,27,32).
Prognosis and the benefit of adjuvant treatment are 
greatly influenced by the final margin status of a resection. 
Prognosis following resection will be impacted by tumor 
type, but also heavily influenced by a number of additional 
considerations including grade, size and location (truncal/
retroperitoneal versus extremity). Patient considerations 
include nutritional status, comorbidities and overall 
performance status. Therefore, in patients presenting with 
a painless mass or a large truncal mass the diagnosis of STS 
must be considered (3,12,14,26,27,29,33). 
Surgical approach by location
In localized extremity tumors
A multimodal approach that attempts to avoid extremity 
amputation has been pursued since the critical work of 
Rosenberg and coworkers (30). Approaches to extremity 
sarcoma with limb-sparing resections tolerating R1 or R2 
resections if critical structures like nerves are involved with 
the use of adjuvant radiation and possibly chemotherapy can 
obtain excellent local control rates in some cases exceeding 
90%. Patient survival following limb-preservation actually 
appears to exceed that associated with amputation, and 
thoughtful limb-preserving resection can be associated with 
excellent functional status with no apparent defect in the 
majority of patients (34,35). Nonetheless, complications 
of resection and radiation can lead to significant problems 
in the extremity including severe edema, chronic wound 
formation and impaired functional capacity (36-38).
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Truncal sarcoma
Outcome for STS of the trunk are generally poorer than 
those of the extremity due to both more advanced stage 
at presentation and troublesome location that can make 
margin-negative extirpation difficult. Technical issues 
include dealing with the attainment of larger size and 
increased difficulty in obtaining negative margins due 
to invasion or intricate involvement with a number of 
vital structures that must be preserved. Local recurrence 
rates exceeding 30% may be expected and, in cases of 
very large, poor-prognosis sarcomas involving numerous 
critical structures, recurrence may be unavoidable and 
surgery is largely a palliative undertaking (39). Post-
operative complications to surgical extirpation are similar 
to those encountered around similar surgeries and the 
organs involved. Surgical complications can include 
bowel obstruction, nerve damage including asthenia, leg 
weakness, and impotence. Use of adjuvant or neoadjuvant 
chemotherapy or radiation therapy generally is associated 
with more complications including enteritis, peripheral 
neuropathy and scarring (4,25,32,36,40). 
Adjacent organ invasion and oligometastatic disease
Surgical extirpation of STS may involve the resection of 
organs that become invaded or compromised. The capacity 
to do so safely and preserve organ function remains a critical 
component of sarcoma surgery and may require resection 
of any combination of involved organs. As a general rule, 
facility of the surgical team to perform each organ-specific 
surgery will be required. The objectives in such scenarios 
remains obtaining a margin-negative resection, thus organ-
preserving approaches are critical (25,41,42).
Importance of specialty centers to optimize patient 
outcomes
Optimizing care for sarcoma patients may best be done 
at centers with experience in their management, both in 
the operating room and with adjuvant therapies. Increased 
recurrence rates have been reported in patients who were 
referred to centers with expertise in sarcoma after definitive 
operation. Mortality rates and amputation rates have 
been demonstrated to be lower at specialty centers (43). 
Specialty centers allow for multidisciplinary teams, as well 
as enrollment in clinical studies (12,43-45). Furthermore, 
preoperative planning with an experienced plastic surgeon 
can lead to improved cosmetic and functional outcomes (46). 
Additional considerations regarding reconstruction are well 
described by Hadad et al. in this special issue (47).
Therapeutic considerations: balancing surgery 
with adjuvant therapies
When patients present with sarcoma, the mainstay therapy 
remains surgery with a goal of providing a margin-negative 
resection of the malignancy. In instances where the tumor is 
not amendable to complete surgical extirpation, particularly 
in instances of high-grade malignancy, the use of adjuvant 
therapies including radiation therapy and chemotherapy 
should be considered.
Radiation
The role of radiation therapy (RT) for extremity sarcoma 
is well established as part of an integrated, limb-preserving 
approach to extremity sarcoma. Doses approaching 
60 cGy and more are generally well tolerated and associated 
with excellent local control rates. The introduction of 
radiation and advanced reconstructive techniques has 
decreased limb amputation rates without sacrificing 
overall survival (30,48). While radiation can be performed 
either preoperatively or postoperatively with equivalent 
disease control, preoperative radiation is associated with 
improved wound healing and less late-term morbidity (49). 
Complications of RT in the extremity include edema, 
failure of wound healing and increased risk of fracture. 
Care must be used in STS patients to minimize radiation to 
bones and risk of pathologic fracture (36,37). 
The role of RT for the treatment of STS of the abdomen, 
chest and retroperitoneum is less well defined and must 
balance toxicity associated with RT, the intrinsic inability 
of solid organs to tolerate RT, and relatively high RT doses 
required to improve local control. RT dose is limited by 
sensitivities of adjacent normal tissues such as bowel, kidney, 
liver, and spinal cord. Similar to the treatment of extremity 
sarcoma, preoperative RT is preferred. New techniques are 
being developed to limit toxicity by sparing normal tissue 
(27,32,39).
Role of chemotherapy
Early studies suggested soft tissue sarcoma prognosis was 
more dependent upon location and grade than sarcoma 
type. Subsequent examination, however, including both 
population-based analyses and molecular analyses of tumor 
mutations, have clarified that adjuvant chemotherapy 
for sarcoma and subsequent prognosis may be critically 
dependent upon tumor type (50-52). Nonetheless, in many 
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instances the best available chemotherapy may be identical 
for a variety of sarcoma types and may not provide any 
therapeutic benefit (53). 
The role of chemotherapy in the neoadjuvant setting is 
controversial; however, strong rationale and emerging data 
favors the use of conventional multi-agent chemotherapy in 
high-risk STS (54). This is based on a recent randomized 
controlled trial comparing the role of conventional 
chemotherapy (anthracycline and ifosfamide) over 
histologically directed chemotherapy in high-risk extremity 
or trunk STS of the 5 most common histological subtypes 
(myxoid liposarcoma, undifferentiated pleomorphic 
sarcoma, synovial sarcoma, leiomyosarcoma, and malignant 
peripheral nerve sheath tumor). The trial was stopped early 
after interim analysis showed a significant benefit in favor 
of conventional chemotherapy over histologically directed 
chemotherapy (55). The use of neoadjuvant chemotherapy 
ultimately should be decided in a multidisciplinary tumor 
board based on individual patient risk and ability to 
tolerate chemotherapy. Surgery remains the only curative-
treatment and central pillar of treatment the paradigm, 
but chemotherapy may have the potential to downsize the 
tumor leading to limb or organ sparing surgery besides 
offering theoretical advantages of limiting micrometastatic 
disease and in-vivo assessment to chemotherapy (56). 
Adjuvant chemotherapy has not been universally adopted 
except for osteosarcoma and Ewing sarcoma. The largest 
meta-analysis so far including 1,953 patients from 18 trials 
has shown a significant benefit in terms of local recurrence 
[odds ratio (OR) =0.73; 95% CI, 0.56–0.94; P=0.02], distant 
and overall recurrence (OR =0.67; 95% CI, 0.56–0.82; 
P=0.0001) in favor of chemotherapy with doxorubicin 
and ifosfamide (40). The impact of chemotherapy on 
survival, however, is modest. Based upon the meta-analytic 
examination, a benefit is only observed with doxirubicin 
and ifosfamide with an absolute risk reduction of death 
from 46% to 40% (P<0.05). This has been estimated to 
translate into a number needed to treat of 17 to benefit one 
patient (40). Therefore, adjuvant chemotherapy is 
reasonable especially for patients with high-risk STS who 
have not received neoadjuvant chemotherapy. Again, the 
decision to give chemotherapy should be individualized 
and made in a multidisciplinary tumor board. Furthermore, 
patients should be made aware of the limited demonstrated 
benefit in overall survival.
Molecular analyses to identify critical mutations that 
lead to the development of various sarcomas and the 
resultant use of targeted therapies have begun to improve 
outcomes for some patients. Today, select mechanistic 
breakthroughs and targeted therapies for specific sarcomas 
has resulted in dramatically different outcomes for certain 
specific tumor types. GIST, for example, has demonstrated 
a radical transformation in patient outcomes following the 
recognition that type III tyrosine kinase receptor mutations, 
particularly of cKit, are present in most GIST tumors 
and targeted therapies can be highly effective in their 
management (57-59). 
Phase II studies have begun to identify new therapies 
for specific sarcoma subtypes. This includes better 
therapies to treat different liposarcoma subtypes (including 
myxoliposarcoma) (60,61). However, due to the rarity of 
STS and its many subtypes, it is difficult to have enough 
power to evaluate chemotherapeutic response to individual 
subtypes, causing them to frequently be lumped together. 
For unresectable advanced STS, chemotherapy with a 
palliative intent (decrease symptoms and improve survival 
and quality of life) is usual treatment. Therefore, current the 
mainstay chemotherapeutic option for most STS remains 
an anthracycline usually doxorubicin, with or without an 
alkylating agent, usually ifosfamide with mesna or olaratumab 
(anti-PDGFRα antibody) (62-64). Combination chemotherapy 
generally offers a higher response rate, however, responses are 
short-lived and OS benefit has not been clearly demonstrated 
for any combination in a phase III randomized clinical trial. 
A phase II trial combining olaratumab with doxorubicin has 
recently shown significant benefit in median PFS (6.6 vs. 
4.1 months; HR =0.67; 95% CI, 0.44–1.02; P=0.05) as well 
as median OS (26.5 vs. 14.7 months; HR =0.46; 95% CI, 
0.30–0.71; P=0.0003) and lead to an accelerated approval of 
olaratumab, but phase III data is awaited. Notably, a recent 
meta-analysis of multi-agent chemotherapy in advanced STS 
including 22 trials (phase II and III) from 1974 to 2016 showed 
that multi-agent chemotherapy was associated with significant 
improvement in OS (HR =0.79; 95% CI, 0.65–0.97; P=0.02) 
and modest improvement in PFS (HR =0.86; 95% CI, 0.73–
1.00; P=0.05). However, subgroup analysis by anthracycline 
containing vs. non-anthracycline containing chemotherapy 
showed no difference in OS or PFS (65).
Alternative therapies for anthracycline-insensitive 
subtypes :  p igmented v i l lonodular  tenosynovi t i s , 
tenosynovial giant cell tumor, dermatofibrosarcoma 
protuberans, neoplasm with perivascular epithelioid cell 
differentiation, endothelioid hemangioendothelioma, 
solitary fibrous tumor, alveolar soft parts sarcoma, and 
extraskeletal myxoid chondrosarcoma with EWSR1-NR4A3 
fusion, are summarized in Table 1 (66-75). These therapies 
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can be used neoadjuvantly to downsize tumors, adjuvantly, 
or to control unresectable disease. Unfortunately, these 
therapies have modest benefit. For example, in the case of 
doxorubicin plus olaratumab, progression free survival is 
increased by 2.5 months (4,64). Targeted therapies, such as 
those used for GIST are needed for other STS subtypes. 
Currently next generation sequencing is being implemented 
to discover potential drug targets (76).
Prognostic factors
The most important prognostic factors are histologic grade, 
tumor size, and stage at the time of diagnosis. Local control 
is the key to a favorable outcome. Improved outcomes for 
patients with head and neck or extremity sarcomas are 
largely due to increased likelihood for earlier diagnosis, the 
ability to more easily excise many extremity tumors with 
negative margins, and a better ability to provide adjuvant 
radiotherapy at higher doses (3,12,14,77). A postoperative 
nomogram can be used to predict 12-year mortality (78).
Conclusions
STS is a rare, but increasingly common malignancy. Early 
diagnosis and referral to a specialized center are crucial for a 
favorable outcome due to the availability of expertise, multi-
modality treatment, and access to clinical trials. While 
advances in adjuvant therapies are being made, complete 
surgical excision remains the mainstay of therapy. Systemic 
therapies for STS subtypes other than GIST are limited in 
benefit; however, successful targeted therapies for GIST 
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Table 1 Summary of current systemic treatment options for patients with STS
STS type First line Second line Third line
Angiosarcoma Doxorubicin Paclitaxel Clinical trial
PVNS/TGCT Imatinib Pazopanib Clinical trial
DFSP Imatinib Pazopanib Clinical trial
PEComa Sirolimus Pazopanib Clinical trial
EHE Sirolimus Sorafenib Pazopanib/clinical trial
SFT/hemangiopericytoma Sunitinib/pazopanib Clinical trial
ASPS Sunitinib/pazopanib Clinical trial
clear cell sarcoma Sunitinib/pazopanib Clinical trial
EMCa Sunitinib/pazopanib Trabectedin Clinical trial
Synovial sarcoma Doxorubicin +/− olaratumab/ifosfamide Pazopanib Clinical trial
liposarcoma Doxorubicin +/− olaratumab/ifosfamide Trabectedin/eribulin Clinical trial
leiomyosarcoma Doxorubicin +/− olaratumab/ifosfamide Gemcitabine + docetaxel Trabectedin/clinical trial
UPS/MFH Doxorubicin +/− olaratumab/ifosfamide Gemcitabine + docetaxel Clinical trial
MPNST Doxorubicin +/− olaratumab/ifosfamide Pazopanib Clinical trial
GIST Imatinib Sorafenib Regorafenib/clinical trial
Other Doxorubicin +/− olaratumab/ifosfamide Pazopanib/trabectedinb Clinical trial
a: with EWSR1-NR4A3 fusion; b: for translocation-associated STS. PVNS, pigmented villonodular tenosynovitis; TGCT, tenosynovial 
giant cell tumor; DFSP, dermatofibrosarcoma protuberans; PEComa, neoplasm with perivascular epithelioid cell differentiation; EHE, 
endothelioid hemangioendothelioma; SFT, solitary fibrous tumor; ASPS, alveolar soft parts sarcoma; EMC, extraskeletal myxoid 
chondrosarcoma; UPS, undifferentiated pleomorphic sarcoma; MFH, malignant fibrous histiocytoma; MPNST, malignant peripheral nerve 
sheath tumor; GIST, gastrointestinal stromal tumor.
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